We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Down
Read MoreHide Full Article
On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG - Free Report) – manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories. The company currently carries a Zacks Rank #3 (Hold).
Of the major positives, Intuitive Surgical has had an impressive run in the bourse of late. A glimpse at the recent price performance reveals a favorable return of 27.7% over the past one year, compared with the Zacks classified Medical Instruments sub-industry’s gain of roughly 2%.
Intuitive Surgical reported stellar first-quarter 2017 results earlier this week, crushing the Zacks Consensus Estimate on both the counts, thanks to the growing adoption of the da Vinci system among physicians and overall growth in global procedures. Intuitive Surgical’s da Vinci surgical system enables minimally invasive surgery that helps avoid the trauma associated with open surgery.
Intuitive Surgical continuously introduces technologies for surgical systems. The company also plans to launch an upgrade – da Vinci X – to its flagship Vinci Xi technology. In this regard, management confirmed the submission of documents for CE Mark approval of Vinci X. Furthermore, the company expects availability of this device in Europe by the second quarter of 2017.
On the flipside, the company expects procedure growth rate to slow down a bit outside the U.S. in the coming quarters. The long sale and purchase order cycle of the da Vinci system has added to the woes.
As a result, the company’s recent earnings estimates for the current year have been a tad bit disappointing, with one analyst moving north and one south over the past two months. As a result, the consensus estimate for the stock inched down around 0.1% over the same time frame.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 58.5%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a stellar one-year return of roughly 15.5%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last 3–5 years of actual earnings) of almost 22%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Down
On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG - Free Report) – manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories. The company currently carries a Zacks Rank #3 (Hold).
Of the major positives, Intuitive Surgical has had an impressive run in the bourse of late. A glimpse at the recent price performance reveals a favorable return of 27.7% over the past one year, compared with the Zacks classified Medical Instruments sub-industry’s gain of roughly 2%.
Intuitive Surgical reported stellar first-quarter 2017 results earlier this week, crushing the Zacks Consensus Estimate on both the counts, thanks to the growing adoption of the da Vinci system among physicians and overall growth in global procedures. Intuitive Surgical’s da Vinci surgical system enables minimally invasive surgery that helps avoid the trauma associated with open surgery.
Intuitive Surgical continuously introduces technologies for surgical systems. The company also plans to launch an upgrade – da Vinci X – to its flagship Vinci Xi technology. In this regard, management confirmed the submission of documents for CE Mark approval of Vinci X. Furthermore, the company expects availability of this device in Europe by the second quarter of 2017.
On the flipside, the company expects procedure growth rate to slow down a bit outside the U.S. in the coming quarters. The long sale and purchase order cycle of the da Vinci system has added to the woes.
As a result, the company’s recent earnings estimates for the current year have been a tad bit disappointing, with one analyst moving north and one south over the past two months. As a result, the consensus estimate for the stock inched down around 0.1% over the same time frame.
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Notably, all the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock represents an impressive one-year return of 58.5%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a stellar one-year return of roughly 15.5%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last 3–5 years of actual earnings) of almost 22%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>